Non-invasive cancer detection system uses Ocean Optics expertise

Sensor Review

ISSN: 0260-2288

Article publication date: 1 January 2006

43

Keywords

Citation

(2006), "Non-invasive cancer detection system uses Ocean Optics expertise", Sensor Review, Vol. 26 No. 1. https://doi.org/10.1108/sr.2006.08726aad.004

Publisher

:

Emerald Group Publishing Limited

Copyright © 2006, Emerald Group Publishing Limited


Non-invasive cancer detection system uses Ocean Optics expertise

Non-invasive cancer detection system uses Ocean Optics expertise

Keywords: Cancer, Sensors

A spectroscopy system from optical sensing specialist Ocean Optics forms the basis of a new, real-time, non-invasive cancer detection system currently undergoing clinical trials. The CancerScanner™ technology uses an Ocean Optics system consisting of light source, probe and spectrometer to detect alterations of cells from normal to pre-cancerous and cancerous conditions in the human body rather than in the lab (Plate 4).

Plate 4 The Cancer Scannere from Ocean Optics

Developed by the Bioscience Division of the US Department of Energy, the technology has been licensed to, and further developed by, SpectraPath Technologies. It is hoped that the system will allow physicians to screen patients quickly, providing instant diagnoses, without requiring invasive and time-consuming biopsies for skin, cervical, brain, oesophageal and colorectal cancers.

At the heart of the system is a USB2000 palm sized spectrometer. It is used to analyse the elastic light scattering (ELS) spectrum produced by cellular nuclei. An LS-1 tungsten halogen light source and single optical fibre probe are used to illuminate the tissue surface. The probe then captures the resulting ELS spectrum. Larger nuclei in cancerous and pre-cancerous cells cause different ELS spectra from normal nuclei.

The CancerScanner™ has so far been successfully tested in both animals and humans for a variety of cancer types. It is small, lightweight, and will be economically practical for hospitals, physician offices and patient services centres.

For more information on the CancerScanner™, including information on the clinical trials, please visit the web site: www.spectrapathtech.com

For enquiries, contact: Nick Barnett, Ocean Optics B.V., Geograaf 24, 6921 EW Duiven, The Netherlands. Tel: +31 26 319 05 00; Fax: +31 26 319 05 05; E-mail: nick.barnett@oceanoptics.com; web site: www.oceanoptics.com

Related articles